WO1997020563A1 - Ligands to enhance cellular uptake of biomolecules - Google Patents
Ligands to enhance cellular uptake of biomolecules Download PDFInfo
- Publication number
- WO1997020563A1 WO1997020563A1 PCT/IB1996/001442 IB9601442W WO9720563A1 WO 1997020563 A1 WO1997020563 A1 WO 1997020563A1 IB 9601442 W IB9601442 W IB 9601442W WO 9720563 A1 WO9720563 A1 WO 9720563A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conjugate
- cells
- tissue
- liver
- neoglycopeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
Definitions
- This invention relates to a delivery system for introducing homogeneous oligonucleoside conjugates that are resistant to biodegradation into cells in a tissue specific manner via ligand directed, receptor mediated, endocytosis pathway.
- the antisense (anticode) or antigene strategy for drug design is based on the sequence-specific inhibition of protein synthesis due to the binding and masking of the target mRNA or genomic DNA, respectively, by the synthetic oligodeoxynucleotides (ol go dN) and their analogs (1) . Implicit in this strategy is the ability of ol go-dNs to cross cellular membranes, thereby gaining access to the cellular compartments containing their intended targets, and to do so in sufficient amounts for binding to those targets to take place.
- oligo-MPs non-ionic oligonucleoside methylphosphonates
- Oligo-MPs are totally resistant to nuclease degradation (3) and are effective antisense agents with demonstrative m vi tro activity against herpes simplex virus type 1 (4) , vesicular stomatitis virus (5) and human immunodeficiency virus ⁇ 6) , and are able to inhibit the expression of ras p21 (7)
- oligo-MPs For oligo-MPs to exhibit antisense activity, however, they must be present in the extracellular medium m concentrations up to 100 ⁇ M ( 4 - 7) . Achieving and maintaining these concentrations for therapeutic purposes presents a number of difficulties, including expense, potential side effects owing to non-specific binding of the oligo-MP and immunogenicity. These difficulties can be circumvented in two ways:
- Both strategies serve to greatly reduce the concentration of the oligo-MP needed to produce an antisense effect and to avoid the toxic side effect with tissue specificity.
- poly-L- lysine and cationic lipids are toxic at concentrations employed for the delivery of DNA and oligo-dNs in vi tro and presumably in vivo ; ( 3 ) the ratio of oligo-dN or DNA to cationic conjugate must be empirically determined in each case.
- oligo dN which are heterogeneous mixtures of conjugates.
- Bonfils et al. describe formation of conjugates between 6-phosphomannosylated protein and oligonucleosides which, because the modification of the protein and the formation of the disulfide link are not regioche ically controlled, yields a mixture of functionally related but structurally different molecules .
- oligodeoxynucleotides or DNA which contain biodegradable phosphodiester internucleotide linkages. Because of this, they may have relatively short half lives within the cell and efficacy is consequently reduced. For example, an all phosphodiester 16-mer, d(T) 16 , was extensively degraded after only two hours in the cell. This disadvantage with oligo-dNs and DNA is well recognized in the antisense community.
- the present invention enables the delivery of biologically stable oligo-MPs, other oligodeoxynucleotide analogs (see Table 1) and other biostable pro-drugs using the delivery strategy described herein.
- the delivery strategy of the present invention obviates all these difficulties because it is chemically defined and structurally homogeneous and it is intended to deliver biologically stable antisense agents and other biostable pro-drugs.
- conjugates available heretofor for delivering oligo dN and oligo dN analogs to their intracellular targets suffer from the disadvantage of being heterogeneous and/or rapidly biodegradable, with the consequences that the most efficacious compounds may be delivered in a dilute form to the target along with extraneous compounds which may be ineffective and/or harmful.
- Such biostable oligomers include, but are not limited to, oligodeoxynucleotide analogs that contain: all 2' -deoxyribose nucleosides and internucleotide linkages that alternate between phosphorothioate and methylphosphonate; all 2' -deoxyribose nucleosides and phosphorothioate internucleotide linkages; all 2'-0- methylribose and phosphorothioate internucleotide linkages .
- the term "efficiently”, as used herein, is intended to mean that, for example, if the conjugate is present in the extracellular medium, then following a 24 hour incubation period at 37°C, the intracellular concentration will be at least approximately 3 times and preferably approximately 10 times the extracellular concentration.
- the linkage between ligand and pro- drug is covalent, and is formed through a cross- linking reagent, which is capable of forming covalent bonds with the ligand and the pro-drug.
- a w de variety of cross-linking reagents are available that are capable of reacting with various functional groups present on the ligand and the pro-drug, thus, many chemically distinct linkages can be constructed.
- the ligand YEE (ah-GalNAc) 3 (see 1; Fig. 1) contains a free amino group at its ammo terminus. It will react regiospecifically with the heterobifunctional cross-linking reagent, SMCC (entry 3; Table 4) , to form an amide bond.
- SMCC heterobifunctional cross-linking reagent
- the pro-drug if chemically modified to contain a free sulhydryl group (for examples see entries 9-14, Table 2) will chemically combine with SMCC to form a thioether linkage.
- the linkage formed between the ligand and pro-drug could be summarized as amide/thioether. It is apparent that hundreds of structures can be formulated by combining the ligands, cross-linking reagents and pro-drugs
- linkages include, but are not restricted to, amide/amide, thioether/a ide, disulfide/amide, amide/thioether, amide/disulfide .
- the linkages can be further categorized as biologically stable (thioether, amine) , somewhat biologically stable (amide) , and biologically labile (disulfide) .
- the delivery system can be modified structurally to function in the various chemical environments encountered in the extra- and intracellular medium.
- the ligands for this delivery system include, but are not restricted to those shown in Fig. 1.
- the ligands consist of a synthetic, chemically defined, structurally homogeneous oligopeptide scaffold that is glycosylated with any of a number of sugar residues including, but not restricted to: glucose; N-acetylglucosamine; galactose; N-acetylgalactosamine,- mannose; and fucose.
- the term “neoglycopeptide”, as used herein, refers to these and similar structures.
- these oligopeptides provide frameworks to construct multivalent ligands with folic acid.
- pro-drug means a compound that, upon hydrolysis or bioreduction of specific chemical linkage (s) , is released from the conjugate to become active or more active than when contained as part of the conjugate.
- chemically uniform means that at least 95% of the delivery assembly, and most preferably 99%, is a single species both in composition and in connectivity. Determination of chemical uniformity is by polyacrylamide gel electrophoresis, reverse-phase high pressure liquid chromatography, nuclear magnetic resonance, mass spectrometry and chemical analysis .
- the phrase "chemically defined and structurally homogeneous” is used interchangeably with “chemically uniform” .
- the term "gene specific”, as used herein, means that the pro-drug is an oligonucleoside (particularly an oligodeoxynucleoside methylphosphonate or analog thereof) having a sequence that is complementary to a portion of a gene or a portion of a mRNA molecule found in the tissue or cell type targeted by the conjugate.
- the formation of a sequence-specific duplex between a gene specific pro-drug and the target mRNA will lead to the supression of expression of the mRNA.
- FIG. 4 PAGE analysis (15% polyacrylamide, 4 V/cm, 2 h) of intermediates in the synthesis of conjugate 10.
- Lane 1 [5' - 32 PJ -labeled 6 (band A) .
- Lane 2 [5' - 32 P] -cystam e adduct (band B) and corresponding thymidine-EDAC adducts (bands C) .
- Lane 3, [5' - 32 P] -thiol 5 (band D) and corresponding thymidine-EDAC adducts (bands E) .
- Lane 4 [5' - 32 P] -conjugate 10 (band F) and corresponding thymidine-EDAC adducts (bands G) .
- Figure 6 24 hour time course for the uptake of conjugate 10 by Hep G2 cells. Cells were incubated at 37°C and the cells collected as described the experimental section. Each data point represents the average of three experiments ⁇ one standard deviation.
- FIG. 7 Tissue specific uptake of conjugate 10 by Hep G2 , HL-60 and HT 1080 cells. Cells were collected and the amount of [ 32 P] determined at 3 and 24 h for each cell line. Experiments were done in triplicate and the data expressed as the average ⁇ one standard deviation.
- FIG. 8 Tissue Distribution of conjugate 10 and conjugate 12, which was produced by removing the terminal GalNAc residues of conjugate 10 with N acetylglucosamidase .
- Panel A Percent initial dose per gram tissue versus time post-injection for conjugate 10
- Panel B Percent initial dose per gram tissue versus time post-injection for conjugate 12.
- Figure 12A Structure of 10. The conjugate was synthesized with radioactive phosphate located on the 5' -OH of the oligoMP moiety. The arrowhead marks the position of the 32 P label.
- Figure 12B Structure of 10 written in abbreviated form. Structures 12 and 3-6 are proposed structures ⁇ of metabolites identified by PAGE analysis.
- Structures 12 and 3-6 are obtained by treating 10 with N-acetylglucosamme, chymotrypsin or 0.1 HC1, respectively.
- FIG. 15 Autoradiographic analysis of the metabolites of 10 in mouse urine. Lane 1, 1; Lane 2, 5 1 treated with N-acetyl-glucosammidase; Lane 3, 1 treated with chymotrypsin; Lane 4, treated with 0.1 N HCl ; Lanes 5-8, urine extractions at 2 hours, 1 hour and 15 minutes post injection. Note that lanes 5 and 6 are replicates. DETAILED DESCRIPTION OF THE INVENTION Abbreviations
- AET 2-am ⁇ nomercaptoethanol (ammoethanethiol) , ATP, adenosine triphosphate
- BAP bacterial alkaline phosphatase
- CPG controlled pore glass support
- DIPEA duspropylethylamine
- D-MEM Dulbecco's modified Eagle's medium
- DMSO dimethyl sulfoxide
- D-PBS Dulbecco's phosphate buffered saline
- DTT dithiothreitol
- EDAC l-ethyl-3- [3 (dimethylammo)propyl] carbodiimide
- EDTA ethylenediammetetraacetate
- FCS fetal calf serum
- GalNAc N-acetylgalactosamme
- - MEM minimal essential medium with Earle's salts
- SMCC N-hydroxysuccinimidyl
- SMCC 4- (N-methylmaleimido) cyclohexyl carboxylate
- SMCC 4- (N-methylmaleimido) cyclohexyl carboxylate
- Pierce Waters SepPak C-18 cartridges were purchased from Millipore Corp.
- YEE (ah-GalNAc) 3 was synthesized according to Lee et al. ( 15a) and was stored at 4°C as an aqueous solution.
- Adenosine triphosphate (ATP) and [ ⁇ - 3 P] -ATP were purchased from P-L Biochemicals, Inc. and Amersham, respectively.
- Polyacrylamide gel electrophoresis was carried out with 20 cm x 20 cm x 0.75 mm gels which contained 15% polyacrylamide, 0.089 M Tris, 0.089 M boric acid, 0.2 mM EDTA (1 x TBE) and 7 M urea. Samples were dissolved in loading buffer containing 90% forma ide, 10% 1 x TBE, 0.2% bromophenol blue and 0.2% xylene blue.
- the final coupling step positioned a phosphodiester linkage between the terminal 5' nucleoside and the adjacent nucleoside which permitted phosphorylation of the 5' terminal hydroxyl group with bacteriophage T4 polynucleotide kinase and ensured reasonable stability of the phosphodiester due to the presence of the 2'-0-methyl group.
- the crude 8-mer was purified by HiTrap Q anion exchange chromatography (load with buffer containing ⁇ 25% acetonitrile; elute with 0.1 M sodium phosphate, pH 5.8) and preparative reverse phase chromatography (Microsorb C-18) using a linear gradient (Solvent A: 50 mM sodium phosphate, pH 5.8, 2% acetonitrile; Solvent B: 50 mM sodium phosphate, pH 5.8, 50% acetonitrile; gradient: 0-60% B in 30 min) .
- the oligomer thus purified was ca 97% pure by analytical HPLC, only contaminated by a small amount of the n-1 species .
- the crude 10 was dissolved in formamide loading buffer (100 ⁇ L) , purified by PAGE (4 V/cm, 1.5 h) , and recovered by the crush and soak method (50% acetornitrile in water) .
- the overall yield of pure 10 was 25%. 10 produced [5' - 32 P] -phosphorylated 6 upon treatment with 0.1 N HC1 (37°C, 1 h) due to hydrolysis of the P-N bond; however, 6 was unreactive towards DTT (50 mM, pH 8, 37°C, 1 h) ,
- Hep G2 Human hepatocellular carcinoma (Hep G2) , human fibrosarcoma (HT 1080) , and human promyleocytic leukemia (HL-60) cells were purchased from ATCC and were maintained in 1 x MEM supplemented with 10% FCS, 1 mM sodium pyruvate, and 0.1 mM non-essential ammo acids (Hep G2) , 1 x D-MEM supplemented with 10% FCS (HT-1080) , or 1 x RPMI supplemented with 10% FCS (HL-60) . Silicon oil was a gift from General Electric (product no. SF 1250) . Cells were counted using a Coulter Cell Counter.
- oligonucleoside analogs are shown in Table 1.
- Table 2 lists 14 examples of 3'- and 5' -phosphate modification, which provide a 1° amine or a thiol for further reaction.
- Table 3 shows the neoglycopeptide, which contains a N-terminal amino group, and four methods for modifying the amine to provide a thiol.
- Table 4 lists several heterobifunctional cross-linking reagents and a Cathepsin D sensitive oligopeptide, which can be used to link the pro-drug to the ligand. It will be readily apparent that many other reagents are available which would be suitable.
- reaction schemes there are two reaction schemes that may be employed to covalently join the oligomer and neoglycopeptide.
- the first entails the coupling of an oligomer and the neoglycopeptide using a heterobifunctional cross-linking reagent and can be classified as a three component reaction.
- This scheme provides for complete regiochemical control of the coupling reaction and yields structurally defined and homogeneous conjugates. For example, if an oligomer of the type shown in Table 1, entry 1, were modified at its 5'- end with a thiol linker (Table 2, entry 10) post-synthetically and conjugated to
- the neoglycopeptide can be modified as shown in Table 3, entries 2-5.
- Activation of the thiol may be accomplished using, for example, 2 , 2 ' -dipyridyl disulfide. Reaction of the activated thiol with any of the 3' or 5' thiol modified oligomers (Table 1, entries 9-14) would provide a disulfide linkage between the oligomer and the neoglycopeptide, as shown below:
- This second scheme provides access to disulfides with varying steric bulk around the sulfur atoms that are not accessible using commercially available crosslinking reagents (cf. Table 4, entries 4-6)
- this reaction scheme can be classified as a two component reaction in which one "half" of the conjugate is modified and then activated for reaction with the other "half". 97/2
- Figure 2 was also incubated with Hep G2 cells under identical conditions. Modification of the 5' -phosphate with ethylenediamme was accomplished by incubation of 5 ' -phoshorylated 2 with 0.1 M EDAC in a buffer containing 0.1 M imidazole at pH 7 at 37°C for 2 h followed by overnight incubation with an aqueous solution 0.3 M ethylenediamine hydrochloride buffered to pH 7.0. (Miller, P.S.; Levis, J. T. , unpublished results) . This modification prevents removal of the 5' -phosphate by cellular phosphatase activity.
- the modified oligo-MP was present at a concentration of 1 ⁇ M in medium containing 2% fetal calf serum (FCS) and incubations were carried out at 37°C.
- FCS fetal calf serum
- the conjugate rapidly associated with the cells when incubated alone, loading the cells in a linear fashion to the extent of 7.8 pmol per 10 6 cells after only two hours ( Figure 5) .
- association of 10 was only 0.42 pmol per 10 6 cells, a value essentially identical to that obtained with the control oligo-MP 11 (0.49 pmol per 10 6 cells) .
- Hep G2 cells were incubated with 11 in the presence of a 10-fold excess of 5 to assess the possibility that despite the absence of a covalent link between 5 and 11, 5 could cause uptake of 11 by the Hep G2 cells.
- the amount of cell associated 11 following a two-hour incubation was only 0.60 pmol per 10 s cells, significantly less than found with the conjugate 10.
- the uptake of 10 by Hep G2 cells for longer times was examined (1 ⁇ M conjugate, 37°C) , and found to be linear up to ca. 24 hours reaching a value of 26.6 pmol per 10 6 cells ( Figure 6) .
- the conjugate 10 associates with Hep G2 cells by binding specifically to the asialoglycoprotein receptor; (2) a covalent link between the oligo-MP and neoglycopeptide is essential for significant enhancement of the association of the oligo-MP with Hep G2 cells; and (3) uptake of 10 by Hep G2 cells does not appear to saturate up to 24 hours under the conditions used in this study.
- Tissue specificity was examined by incubating three human cell lines, Hep G2, HL-60 and HT 1080, in medium containing 1 ⁇ M conjugate 10 and 2% FCS at 37°C for 3 and 24 hours. The only cell line to exhibit significant uptake of 10 was Hep G2. After incubation for 3 and 24 hours, 8.5 and 26.7 pmol per 10 6 cells, respectively, was associated with the cells ( Figure 7) .
- oligo-MP oligodeoxynucleoside methylphosphonate
- lTpT 7 was 5' end- labeled with [ ⁇ - 32 P]-ATP and ATP to give having a specific activity of 300 ⁇ Ci/14 nmol (the * indicates the position of the radioactive nuclide) .
- the 5' phosphate was modified with cystamine in the presence of 1-methylimidazole and water soluble carbodiimide.
- the resulting disulfide was reduced with excess dithiothreitol and conjugated with the ligand, YEE (ah-GalNAc) 3 , using the heterobifunctional cross-linking reagent SMCC.
- the conjugate (1) was purified by polyacrylamide gel electrophoresis, extracted from the gel and desalted using a SepPak cartridge.
- the pure conjugate was characterized both enzymatically and chemically.
- a portion of the conjugate was treated with N-acetylglucosamidase in order to completely remove the GalNAc residues (12) .
- Both 10 and 12 were >99% pure as judged by PAGE analysis.
- the solutions containing the conjugates were placed in sterile test tubes and lyophilized under aseptic conditions in preparation for the whole animal biodistribution and pharmacokinetic experiments.
- the conjugates 10 and 12 were redissolved in sterile water. Each mouse received 0.11 ⁇ Ci (7 pmol) of conjugate 10 and 0.036 ⁇ Ci (1.2 pmol) of 12 by tail vein injection. Sequential blood, bladder/urine and tissue samples (liver, spleen, kidney and muscle) were collected at 15, 30, 60, 120 and 1440 min post-injection. Three mice were used for each time point for a total of 30 mice. The mouse was killed by cervical dislocation at the time of sampling. Whole wet tissue was weighed in a scintillation vial and digested at 50°C with NCS solubilizer.
- the samples were decolorized, dissolved in scintillation cocktail and the levels of radioactivity determined by scintillation counting.
- the raw data was converted into percent initial dose per gram of tissue, except for that obtained from the bladder, which was expressed as percent initial dose per tissue sample owing to the difficulty of obtaining these tissues intact (see Figure 8) .
- Conjugate 12 which lacks the three GalNAc residues, rapidly associated with the bladder/urine and, to a lesser extent, the kidney, and showed no specificity for the liver. For example, at 30 min the percent of initial dose per gram of tissue was 40%, 5.0% and 1.1% for the bladder/urine, kidney and liver, respectively.
- conjugate 10 associates specifically with the liver; (2) association of conjugate 10 is wholly dependent upon the presence of the GalNAc residues on the ligand; (3) conjugate 10 or, more likely, its metabolites, are cleared from the liver within 24 hours and eliminated from the mouse via the kidney and, hence, finds its way into the bladder and urine. Furthermore, owing to the low level of radioactivity found in the blood versus the large amount of radioactivity associated with the liver, it can be concluded that conjugate 10 is delivered into the hepatocytes rather than simply associated with the liver within the interstitial space.
- Synthesis of SMCC-YEE(ah-GalNAc) 3 (Alternative method) . About 1-2 ⁇ mole of YEE (ah-GalNAc) 3 was dried into a 1 mL glass Reacti-vial. To this solution, anhydrous DMSO (250 ⁇ L) and anhydrous DIPEA (3 ⁇ L) was added, then treated with 150 ⁇ L of a solution containing vacuum-dried SMCC (6 mg) in anhydrous DMSO. The mixture was vortexed briefly and left stand at room temperature for 2 hours.
- oligonucleotide tracer unit in the form of a 3' -conjugate was used so that phosphorylatable 3 ' -end could be used to introduce the radioactive 3 P label were also employed in this study.
- modified oligomers were synthesized on a solid-phase DNA synthesizer, using corresponding phosphoramidites and methylphosphonamidites from a commercial source (Glen Research) .
- the tracer was synthesized ( Figure 10) using dT-5 ' -Lcaa-CPG as the solid phase and dT-5'-CE phosphoramidite, 5'-DMT-5-
- the Beaucage reagent (Glen Research) was substituted for the low moisture oxidizer to effect sulfurization of the phosphite to give the phosphorothioate according to standard established procedures.
- the oligomers were deprotected under Genta one-pot method and were purified by trityl-on procedures. Final purification were conducted using a preparative reversed-phase C18 column. The reduction of the disulfide moiety to the thiol was effected by the treatment of the 5 ' -disulfide-containing oligomers with DTT.
- a 2.5 OD 260 (-16 nmole) disulfide oligomer was dissolved in 400 ⁇ L of freshly prepared and degassed 50 mM DTT solution in 10 mM sodium phosphate, pH 8. The mixture was incubated at 37°C for 2 hr. Quantitative reduction were confirmed by reversed-phase HPLC analysis, which shows that the thiol oligomers elute faster than the parent disulfide oligomers. The thiol oligomer was then purified on a Sephadex G-25 column (10x300mm) to remove DTT and salts. Column packing and sample elution were effected by the use of degassed 20% ethanol-water. The G-25 fraction containing the pure thiol oligomer was used immediately in the next reaction to minimize unwanted oxidation.
- Oligonucleotides (compound 14, shown as lc in Table 5) .
- the G-25 fraction containing 1.8 OD 260 (12 nmole) pure thiol oligomer (lb) was mixed with SMCC-YEE (ah-GalNAc) 3 (50 nmole) immediately after it was collected.
- the mixture was concentrated to dryness in a speed-vac.
- the residue was dissolved in 100 ⁇ l of degassed 50% CH 3 CN containing 0.1 M sodium phosphate, pH 7.
- the solution was further degassed in a speed-vac by applying vacuum for about 5 min.
- the solution was then capped tight and incubated at room temperature overnight to allow conjugation to complete.
- Hep G2 2.2.15 a human hepatocellular carcinoma cell line stably transfected with human hepatitis B virus DNA (22) , was a gift of Dr. G.Y. Wu.
- Other lines of suitable cells are known to persons of skill in the art, for example PLC/PRF/5 (Alexander cells) , a human hepatoma secreting hepatitis B surface antigen, has been described (23) and is available from the American Type Culture Collection.
- Hep G2 2.2.15 cells were maintained in IX Dulbecco's Modified Eagles Medium supplemented with 10% fetal calf serum. All other materials used were identical to those cited in the Cellular Uptake section above.
- HepG2 2.2.15 cells were inoculated into 2 cm 2 wells and grown in IX DMEM containing 10% FCS to a density of 10 5 cells per well. The maintenance media was aspirated and the cells were incubated at 37°C with 0.5 ml DMEM containing 2% FCS and made luM in [5' 32 p] with lc, Id, or le. All other methods were identical to those followed in Example 4. In order to measure the efflux of lc, HepG2
- 2.2.15 cells were seeded and incubated with 1 uM of the conjugated oligomer for twenty-four hours as described above. The oligomer containing medium was then aspirated and the cells washed twice and subsequently incubated in 0.5 ml maintenance medium. At designated times the cells were collected and lysed as described in the Cellular Uptake section of the Provisional Application. Efflux was determined by monitoring the amount of radioactivity and by inference the concentration of the conjugated oligomer in the cell lysate.
- the results of this experiment were very similar to those performed with the modified oligo-mp.
- the conjugated 2'OMe alternating oligomer (Id) was taken up by Hep2G 2.2.15 cells in a linear fashion to the extent of 7.7 pmoles/10 6 cells after two hours incubation (Table 6) .Uptake increased to 14.2 pmoles/10 6 cells in three hours and peaked at 28.5 pmoles/106 cells after twenty-four hours incubation.
- EDA modified oligomer (le) associated with Hep G2 2.2.15 cells to the extent of 0.275 pmoles/10 6 cells after two hours, .978 pmoles/10 6 cells after three hours and .385 pmoles/10 6 cells after twenty-four hours incubation (Table 6) .
- neoglycopeptide 5 is capable of delivering a biostable oligomer consisting of all 2'-0- methylribose nucleosides and alternating methyl phosphonate, phosphodiester internucleotide linkages to hepatocytes in a highly efficient manner.
- the placement of a phosphorothioate protected tracer at the 3' end of the conjugated oligomer (lc) has no significant impact on cellular uptake.
- these studies also show that the internalized oligomer exits the cell reaching a value that is 58% of the peak uptake twenty-four hours after treatment was terminated.
- a delivery vehicle of the invention i.e, which contains the asialoglycoprotein ligand, YEE (ah-GalNAc) 3 radiolabeled with 32 P, to deliver synthetic oligo-MPs specifically to the liver of mice and to examine the metabolic fate of this conjugate in isolated Hep G2 cells and in vivo in mouse liver and urine.
- a conjugate which lacks the three terminal Gal NAc residues was also synthesized. This sugarless conjugate served as a control for the study of ligand (GalNAc) -specific uptake in mice .
- mice Male CD-I mice (Charles River) , weighing 22 to 35 g, received a single injection via tail vein of 7-30 picomoles of [ 32 P] - [YEE(ah-GalNAc) 3 ] -SMCC-AET- pU"px T 7 (10) or 7 p ole of [ 32 P] - [YEE (ah) 3 ] SMCC-AET-pUTMpT 7 (12) contained in 0.2 mL of saline. The mice were sacrificed by cervical dislocation at 15, 30 and 60 minutes and 2, 4, 6 and 24 hours. Blood, liver, kidneys, spleen, muscle, upper and lower gastrointestinal tract and feces were collected and weighed. Representative samples from these organs and tissues were weighed and placed in glass vials. In order to collect the urine (2 hours post injection) , the external urethra of the mice was ligated under short ether anesthesia and,
- Example 14 Analysis of Conjuga te Metabolism .
- Animals were sacrificed after 15, 60 and 120 minutes.
- Livers and bladders were collected as before, placed into plastic vials and immediately frozen (80°C) . Samples of liver were thawed to 0°C and weighed (average mass 0.25 g) .
- the tissue was homogenized (Polytron PCU-2-110 Tissue Homogenizer) in 4 volumes of acetonitrile/water (1:1) .
- Tissue debris was removed by centrifugation (10,000g, 20 min, 0°C; Sorval Model RC-5B Refrigerated Superspeed Centrifuge) .
- the supernatent was removed and the extraction procedure repeated. Typical recovery of radioactivity from the liver samples was 3 90% as judged by comparison of aliquots of decolorized homogenate and supernatant.
- a portion of the supernatent was filtered through a Centricon filter (30,000 MWC; 20 min, 0°C, 10,000g; Her l Z 360 K Refrigerated Microcentrifuge) and lyophilized.
- mice were injected via tail vein with radiolabeled conjugate as described above and the amount of radioactivity associated with each organ determined by scintillation counting.
- Table 9 shows the conjugate associates to the greatest extent with the liver, reaching a value of 69.9% of the injected dose 15 minutes post-injection.
- the ranking of total radioactivity in the other tissues measured at 15 minutes post-injection was, in decreasing order: muscle > kidney > blood > spleen.
- the peak value of radioactivity for the urine was 28% of the injected dose and was reached after 30 minutes.
- the amount of radioactivity associated with the kidneys and blood decreased over time.
- Figure 13 shows the results of PAGE analysis of the metabolism of conjugate 10 following incubation with Hep G2 cells for 2-24 hours.
- Three classes of metabolites are identified (labeled I-III in Fig. 13) according to their electrophoretic mobility versus control reactions.
- Class I appears to consist of four chemically distinct species in which 1 and 2 predominate at all time points. Distribution of 1 and 2 is approximately 1:1 at the earliest time points shifting to predominantly 2 at longer incubation times.
- a third metabolite of this class (3, figure 12b) ) , which co-migrates with a material produced by chymotrypsin digestion of 1, is also observed at each time point.
- the conjugate appears to be largely intact with a small but significant amount of material converted to two species, both of which do not co-migrate with any of the controls. The relative amounts of each appear to remain constant over the course of the experiment. No Class II, II' or III metabolites are observed in the mouse urine.
- [ 32 P] -labeled conjugate 10 which is chemically defined and homogeneous, is capable of crossing the cellular membrane of Hep G2 cells in a manner that is both ligand and cell-type specific.
- a logical extension of these investigations was to determine the tissue distribution of 1 in vivo and to compare the metabolic fate of 10 in vi tro and in vivo and to compare the data with those obtained with conjugate 12 which lacks the three terminal GalNAc residues.
- the in vivo tissue distribution data confirm the results obtained with cultured human cells.
- Highly selective targeting of the oligodeoxynucleoside methylphosphonate to the liver (70 ⁇ 10% of i.d.) was effectively achieved through covalent attachment of the oligomer and the asialoglycoprotein receptor (ASGP) ligand, YEE(ah-GalNAc) 3 .
- ASGP asialoglycoprotein receptor
- YEE(ah-GalNAc) 3 asialoglycoprotein receptor
- mice were injected with conjugate 12, which lacks the three terminal GalNAc residues, and therefore should not be recognized by ASGP receptor. As anticipated, little radioactivity was detected in the liver and a far greater amount of radioactivity was associated with other tissues (Table 11) . This result extended our previous findings that the targeting of the radiolabeled oligo-MP to hepatocytes was a consequence of its covalent attachment to the ligand.
- Cleavage at this site would release the terminal seven nucleotides of the oligo-MP from the remainder of 1 and, most importantly, produce a relatively low molecular weight species bearing a single nucleotide containing the radiolabeled phosphate (6, Figure 12b)) . Further degradation of the ligand would produce the multiple species identified as Class II metabolites. Class III metabolites, observed in Hep G2 cells only, appear to be high molecular weight species containing radioactive phosphorous that migrate a short distance into the gel. Release of radioactive phosphate from 1 and its subsequent incorporation into high molecular weight cellular structures (nucleic acids or proteins) would account for this band.
- 20 b Value is the average of two independent determinations.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96941146A EP0862439A4 (en) | 1995-11-22 | 1996-11-22 | Ligands to enhance cellular uptake of biomolecules |
AU10393/97A AU1039397A (en) | 1995-11-22 | 1996-11-22 | Ligands to enhance cellular uptake of biomolecules |
JP9521121A JP2000501414A (en) | 1995-11-22 | 1996-11-22 | Ligand enhances cellular uptake of biomolecules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US748095P | 1995-11-22 | 1995-11-22 | |
US60/007,480 | 1995-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997020563A1 true WO1997020563A1 (en) | 1997-06-12 |
Family
ID=21726432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1996/001442 WO1997020563A1 (en) | 1995-11-22 | 1996-11-22 | Ligands to enhance cellular uptake of biomolecules |
Country Status (8)
Country | Link |
---|---|
US (1) | US5994517A (en) |
EP (1) | EP0862439A4 (en) |
JP (1) | JP2000501414A (en) |
CN (1) | CN1120707C (en) |
AU (1) | AU1039397A (en) |
CA (1) | CA2238379A1 (en) |
TW (1) | TW520293B (en) |
WO (1) | WO1997020563A1 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054731A2 (en) * | 2000-01-28 | 2001-08-02 | National University Of Singapore | Ligand conjugates and methods for preparing same |
US6906182B2 (en) | 2000-12-01 | 2005-06-14 | Cell Works Therapeutics, Inc. | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use |
US7153977B2 (en) | 2000-01-28 | 2006-12-26 | National University Of Singapore | Ligands and methods for preparing same |
WO2014179620A1 (en) | 2013-05-01 | 2014-11-06 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
WO2015168172A1 (en) | 2014-04-28 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
WO2015168618A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
WO2015168589A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
EP3034510A1 (en) * | 2004-04-30 | 2016-06-22 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
WO2017053722A1 (en) | 2015-09-24 | 2017-03-30 | Ionis Pharmaceuticals, Inc. | Modulators of kras expression |
WO2017079745A1 (en) | 2015-11-06 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
WO2018014041A2 (en) | 2016-07-15 | 2018-01-18 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of smn2 |
US9879265B2 (en) | 2013-06-27 | 2018-01-30 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
US9943604B2 (en) | 2013-09-20 | 2018-04-17 | Ionis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
US10246709B2 (en) | 2016-03-07 | 2019-04-02 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
US10280423B2 (en) | 2014-05-01 | 2019-05-07 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor B expression |
US10294474B2 (en) | 2016-09-02 | 2019-05-21 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
WO2019140452A1 (en) | 2018-01-15 | 2019-07-18 | Ionis Pharmaceuticals, Inc. | Modulators of dnm2 expression |
US10358643B2 (en) | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
WO2019217527A1 (en) | 2018-05-09 | 2019-11-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing fxi expression |
US10557137B2 (en) | 2015-11-06 | 2020-02-11 | Ionis Pharmaceuticals, Inc. | Modulating apolipoprotein (a) expression |
WO2020033748A1 (en) | 2018-08-08 | 2020-02-13 | Arcturus Therapeutics, Inc. | Compositions and agents against nonalcoholic steatohepatitis |
US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
WO2020061200A1 (en) | 2018-09-19 | 2020-03-26 | Ionis Pharmaceuticals, Inc. | Modulators of pnpla3 expression |
WO2021074772A1 (en) | 2019-10-14 | 2021-04-22 | Astrazeneca Ab | Modulators of pnpla3 expression |
EP3862362A2 (en) | 2014-05-01 | 2021-08-11 | Ionis Pharmaceuticals, Inc. | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression |
US11149264B2 (en) | 2018-02-12 | 2021-10-19 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
US11299737B1 (en) | 2020-02-28 | 2022-04-12 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating SMN2 |
US11400161B2 (en) | 2016-10-06 | 2022-08-02 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
US11447521B2 (en) | 2020-11-18 | 2022-09-20 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
EP4092119A2 (en) | 2015-07-10 | 2022-11-23 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
WO2023056440A1 (en) | 2021-10-01 | 2023-04-06 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
EP4309732A2 (en) | 2017-03-24 | 2024-01-24 | Ionis Pharmaceuticals, Inc. | Modulators of pcsk9 expression |
US12013403B2 (en) | 2014-09-12 | 2024-06-18 | Biogen Ma Inc. | Compositions and methods for detection of SMN protein in a subject and treatment of a subject |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030119724A1 (en) * | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
CN1058722C (en) * | 1998-12-29 | 2000-11-22 | 四川省天然药物研究所 | Method for preparing one new compound and its use as oral heavy metal excretion promoter |
US8541548B2 (en) * | 1999-06-07 | 2013-09-24 | Arrowhead Madison Inc. | Compounds and methods for reversible modification of biologically active molecules |
US20080281041A1 (en) * | 1999-06-07 | 2008-11-13 | Rozema David B | Reversibly Masked Polymers |
US6777387B2 (en) | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
US6756037B2 (en) | 2000-03-31 | 2004-06-29 | Enzon, Inc. | Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups |
DE60223499T2 (en) * | 2001-02-20 | 2008-10-16 | Enzon, Inc. | TERMINAL BRANCHED, POLYMER LEFT AND THESE POLYMERS CONJUGATED |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8008355B2 (en) * | 2002-03-11 | 2011-08-30 | Roche Madison Inc. | Endosomolytic poly(vinyl ether) polymers |
US8138383B2 (en) * | 2002-03-11 | 2012-03-20 | Arrowhead Madison Inc. | Membrane active heteropolymers |
AU2003277153A1 (en) | 2002-09-27 | 2004-04-19 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
JP4597976B2 (en) | 2003-04-17 | 2010-12-15 | アルナイラム ファーマシューティカルズ インコーポレイテッド | Modified iRNA agent |
US8796436B2 (en) | 2003-04-17 | 2014-08-05 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
WO2006104530A1 (en) * | 2005-03-28 | 2006-10-05 | Cell Works Therapeutics, Inc. | Therapeutics targeted to renal cells |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US20080070792A1 (en) | 2006-06-14 | 2008-03-20 | Roland Stoughton | Use of highly parallel snp genotyping for fetal diagnosis |
US8017109B2 (en) * | 2006-08-18 | 2011-09-13 | Roche Madison Inc. | Endosomolytic poly(acrylate) polymers |
CN102614528B (en) * | 2006-08-18 | 2014-02-26 | 箭头研究公司 | Polyconjugates for in vivo delivery of polynucleotides |
AU2008242583B2 (en) | 2007-04-23 | 2013-10-10 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
AU2008340354B2 (en) * | 2007-12-04 | 2014-04-17 | Alnylam Pharmaceuticals, Inc. | Folate-iRNA conjugates |
EP4074344A1 (en) | 2007-12-04 | 2022-10-19 | Arbutus Biopharma Corporation | Targeting lipids |
EP3604533A1 (en) * | 2008-04-11 | 2020-02-05 | Arbutus Biopharma Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
EP2952589B1 (en) | 2008-09-20 | 2018-02-14 | The Board of Trustees of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
EP3335715A3 (en) | 2008-10-15 | 2018-08-08 | Ionis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
AU2010208381A1 (en) | 2009-01-28 | 2011-08-04 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
AU2010208295A1 (en) | 2009-01-28 | 2011-08-04 | Smartcells, Inc. | Polynucleotide aptamer-based cross -linked materials and uses thereof |
MA33064B1 (en) | 2009-01-28 | 2012-02-01 | Smartcells Inc | Concomitant drug control management system |
WO2010088286A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
SG173117A1 (en) | 2009-01-28 | 2011-08-29 | Smartcells Inc | Crystalline insulin-conjugates |
EP2408470A4 (en) | 2009-03-20 | 2012-08-29 | Smartcells Inc | Soluble non-depot insulin conjugates and uses thereof |
WO2010107519A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
US8790916B2 (en) * | 2009-05-14 | 2014-07-29 | Genestream, Inc. | Microfluidic method and system for isolating particles from biological fluid |
DE102009054096A1 (en) * | 2009-11-12 | 2011-05-19 | Dentaurum Gmbh & Co. Kg | Method of making an orthodontic element |
DK2539451T3 (en) * | 2010-02-24 | 2016-04-04 | Arrowhead Res Corp | Compositions for targeted delivery of siRNA |
US8933207B2 (en) | 2010-07-28 | 2015-01-13 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
JP2013541500A (en) | 2010-07-28 | 2013-11-14 | スマートセルズ・インコーポレイテツド | Recombinant lectins, binding site modified lectins and their uses |
WO2012015692A2 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
US9243246B2 (en) | 2010-08-24 | 2016-01-26 | Sirna Therapeutics, Inc. | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
JP6126009B2 (en) | 2010-11-17 | 2017-05-10 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Regulation of α-synuclein expression |
WO2013086354A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
EP2920304B1 (en) | 2012-11-15 | 2019-03-06 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
EP2951305B1 (en) | 2013-01-30 | 2018-08-15 | F.Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
CN105164261B (en) | 2013-05-01 | 2022-03-18 | 莱古路斯治疗法股份有限公司 | Compounds and methods for enhanced cellular uptake |
AU2014259954B2 (en) | 2013-05-01 | 2019-11-07 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-122 |
EP3730619A1 (en) | 2013-06-21 | 2020-10-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
MX366852B (en) | 2013-10-04 | 2019-07-25 | Merck Sharp & Dohme | Glucose-responsive insulin conjugates. |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
EP3060664B1 (en) | 2013-10-25 | 2021-07-07 | Sanofi | Microrna compounds and methods for modulating mir-21 activity |
EP3978610A3 (en) | 2014-03-19 | 2022-08-24 | Ionis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
JP6622214B2 (en) | 2014-04-01 | 2019-12-18 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Composition for modulating SOD-1 expression |
EP4223315A3 (en) | 2014-05-01 | 2023-08-23 | Ionis Pharmaceuticals, Inc. | Method for synthesis of reactive conjugate clusters |
GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
US9487783B2 (en) | 2014-08-07 | 2016-11-08 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2016112132A1 (en) | 2015-01-06 | 2016-07-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
US10407678B2 (en) | 2015-04-16 | 2019-09-10 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
EP4285912A3 (en) | 2015-09-25 | 2024-07-10 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
US10577388B2 (en) | 2015-10-02 | 2020-03-03 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugation process |
EP3394258B1 (en) | 2015-10-22 | 2021-09-22 | Roche Innovation Center Copenhagen A/S | In vitro toxicity screening assay |
WO2017096395A1 (en) | 2015-12-04 | 2017-06-08 | Ionis Pharmaceuticals, Inc. | Methods of treating breast cancer |
CA3006599A1 (en) | 2016-01-05 | 2017-07-13 | Ionis Pharmaceuticals, Inc. | Methods for reducing lrrk2 expression |
KR20180103166A (en) * | 2016-01-29 | 2018-09-18 | 교와 핫꼬 기린 가부시키가이샤 | Nucleic acid complex |
RS61528B1 (en) | 2016-03-14 | 2021-04-29 | Hoffmann La Roche | Oligonucleotides for reduction of pd-l1 expression |
WO2017161168A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Modulation of dyrk1b expression |
AU2017234678A1 (en) | 2016-03-16 | 2018-08-16 | Ionis Pharmaceuticals, Inc. | Methods of modulating KEAP1 |
US11105794B2 (en) | 2016-06-17 | 2021-08-31 | Hoffmann-La Roche Inc. | In vitro nephrotoxicity screening assay |
US11236339B2 (en) | 2016-06-17 | 2022-02-01 | Ionis Pharmaceuticals, Inc. | Modulation of GYS1 expression |
CN109312403B (en) | 2016-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | In vitro nephrotoxicity screening assay |
JOP20190104A1 (en) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
WO2018102745A1 (en) | 2016-12-02 | 2018-06-07 | Cold Spring Harbor Laboratory | Modulation of lnc05 expression |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
AU2018318231A1 (en) | 2017-08-18 | 2020-02-13 | Ionis Pharmaceuticals, Inc. | Modulation of the notch signaling pathway for treatment of respiratory disorders |
US10517889B2 (en) | 2017-09-08 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Modulators of SMAD7 expression |
TWI809004B (en) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | Compounds and methods for reducing snca expression |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
JP2021511029A (en) | 2018-01-18 | 2021-05-06 | ロシュ イノベーション センター コペンハーゲン エーエス | Antisense oligonucleotide targeting SREBP1 |
CA3090517A1 (en) | 2018-02-14 | 2019-08-22 | Deep Genomics Incorporated | Oligonucleotide therapy for wilson disease |
TWI840345B (en) | 2018-03-02 | 2024-05-01 | 美商Ionis製藥公司 | Modulators of irf4 expression |
US11732260B2 (en) | 2018-03-02 | 2023-08-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-β precursor protein |
US11661601B2 (en) | 2018-03-22 | 2023-05-30 | Ionis Pharmaceuticals, Inc. | Methods for modulating FMR1 expression |
JP7275164B2 (en) | 2018-04-11 | 2023-05-17 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Regulators of EZH2 expression |
JP2021522808A (en) | 2018-05-07 | 2021-09-02 | ロシュ イノベーション センター コペンハーゲン エーエス | Massively parallel discovery method for oligonucleotide therapeutic agents |
US12005120B2 (en) | 2018-05-08 | 2024-06-11 | Regulus Therapeutics Inc. | Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect |
CR20200604A (en) | 2018-05-09 | 2021-02-09 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
CA3103429A1 (en) | 2018-06-14 | 2019-12-19 | Don W. Cleveland | Compounds and methods for increasing stmn2 expression |
TWI833770B (en) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | Compounds and methods for reducing lrrk2 expression |
WO2020007826A1 (en) | 2018-07-05 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting mbtps1 |
WO2020011745A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting cers6 |
WO2020011744A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting cers5 |
US20220098581A1 (en) | 2018-07-20 | 2022-03-31 | Regulus Therapeutics Inc. | Methods for Oral Delivery of Oligonucleotides |
AU2019310097A1 (en) | 2018-07-25 | 2021-02-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ATXN2 expression |
MX2021001056A (en) | 2018-08-13 | 2021-04-12 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF. |
TW202028222A (en) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Modulators of foxp3 expression |
EA202191342A1 (en) | 2018-11-15 | 2021-08-10 | Айонис Фармасьютикалз, Инк. | IRF5 EXPRESSION MODULATORS |
BR112021013369A2 (en) | 2019-01-31 | 2021-09-21 | Ionis Pharmaceuticals, Inc. | YAP1 EXPRESSION MODULATORS |
US11279932B2 (en) | 2019-02-27 | 2022-03-22 | Ionis Pharmaceuticals, Inc. | Modulators of MALAT1 expression |
JP7550165B2 (en) | 2019-03-29 | 2024-09-12 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Compounds and methods for modulating UBE3A-ATS |
BR112021018739A2 (en) | 2019-03-29 | 2022-05-03 | Dicerna Pharmaceuticals Inc | Compositions and methods for treating kras-associated diseases or disorders |
MX2021013418A (en) | 2019-05-03 | 2021-12-10 | Dicerna Pharmaceuticals Inc | Double-stranded nucleic acid inhibitor molecules with shortened sense strands. |
WO2021021673A1 (en) | 2019-07-26 | 2021-02-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gfap |
MX2022013707A (en) | 2020-05-01 | 2022-12-07 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating atxn1. |
WO2021254360A1 (en) * | 2020-06-16 | 2021-12-23 | 上海拓界生物医药科技有限公司 | Carbohydrate molecular cluster and preparation method therefor and medical use thereof |
TW202216996A (en) | 2020-06-29 | 2022-05-01 | 美商Ionis製藥公司 | Compounds and methods for modulating plp1 |
WO2022133278A2 (en) | 2020-12-18 | 2022-06-23 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating factor xii |
BR112023026050A2 (en) | 2021-06-18 | 2024-03-05 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS TO REDUCE IFNAR1 EXPRESSION |
CA3237769A1 (en) | 2021-11-10 | 2023-05-19 | University Of Rochester | Gata4-targeted therapeutics for treatment of cardiac hypertrophy |
WO2023086295A2 (en) | 2021-11-10 | 2023-05-19 | University Of Rochester | Antisense oligonucleotides for modifying protein expression |
US20230372508A1 (en) * | 2022-05-19 | 2023-11-23 | Olix Us, Inc. | Linkers coupling functional ligands to macromolecules |
WO2024050261A1 (en) | 2022-08-29 | 2024-03-07 | University Of Rochester | Antisense oligonucleotide-based anti-fibrotic therapeutics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554386A (en) * | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2727573B2 (en) * | 1988-07-29 | 1998-03-11 | 株式会社島津製作所 | Method for producing oligonucleotide probe |
FR2721931B1 (en) * | 1994-06-30 | 1996-08-02 | Commissariat Energie Atomique | CONJUGATES OF DIPHOSPHATE OR TRIPHOSPHATE ANALOGS WITH ENZYMES OR ANTIGEN PROTEINS AND IMMUNOASSAY USING SUCH CONJUGATES |
-
1996
- 1996-11-22 AU AU10393/97A patent/AU1039397A/en not_active Abandoned
- 1996-11-22 EP EP96941146A patent/EP0862439A4/en not_active Withdrawn
- 1996-11-22 WO PCT/IB1996/001442 patent/WO1997020563A1/en active Application Filing
- 1996-11-22 CA CA002238379A patent/CA2238379A1/en not_active Abandoned
- 1996-11-22 JP JP9521121A patent/JP2000501414A/en not_active Withdrawn
- 1996-11-22 TW TW085114401A patent/TW520293B/en not_active IP Right Cessation
- 1996-11-22 US US08/755,062 patent/US5994517A/en not_active Expired - Fee Related
- 1996-11-22 CN CN96199495A patent/CN1120707C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554386A (en) * | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
Non-Patent Citations (7)
Cited By (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054731A3 (en) * | 2000-01-28 | 2002-12-12 | Univ Singapore | Ligand conjugates and methods for preparing same |
US7153977B2 (en) | 2000-01-28 | 2006-12-26 | National University Of Singapore | Ligands and methods for preparing same |
SG148022A1 (en) * | 2000-01-28 | 2008-12-31 | Univ Singapore | Novel ligands and methods for preparing same |
WO2001054731A2 (en) * | 2000-01-28 | 2001-08-02 | National University Of Singapore | Ligand conjugates and methods for preparing same |
US6906182B2 (en) | 2000-12-01 | 2005-06-14 | Cell Works Therapeutics, Inc. | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use |
US7262177B2 (en) | 2000-12-01 | 2007-08-28 | Cell Works Therapeutics, Inc. | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use |
EP3034510A1 (en) * | 2004-04-30 | 2016-06-22 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
WO2014179625A1 (en) | 2013-05-01 | 2014-11-06 | Isis Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION |
US9957504B2 (en) | 2013-05-01 | 2018-05-01 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating apolipoprotein (a) expression |
EP3524680A1 (en) | 2013-05-01 | 2019-08-14 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ttr expression |
US9127276B2 (en) | 2013-05-01 | 2015-09-08 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
US9145558B2 (en) | 2013-05-01 | 2015-09-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating HBV expression |
US9163239B2 (en) | 2013-05-01 | 2015-10-20 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating apolipoprotein C-III expression |
EP3633039A1 (en) | 2013-05-01 | 2020-04-08 | Ionis Pharmaceuticals, Inc. | Compositions and methods |
US11851655B2 (en) | 2013-05-01 | 2023-12-26 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating apolipoprotein (a) expression |
US10683499B2 (en) | 2013-05-01 | 2020-06-16 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating TTR expression |
US9181549B2 (en) | 2013-05-01 | 2015-11-10 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
US9181550B2 (en) | 2013-05-01 | 2015-11-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating apolipoprotein (a) expression |
WO2014179629A2 (en) | 2013-05-01 | 2014-11-06 | Isis Pharmaceuticals, Inc. | Compositions and methods |
WO2014179626A2 (en) | 2013-05-01 | 2014-11-06 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating apolipoprotein c-iii expression |
US11299736B1 (en) | 2013-05-01 | 2022-04-12 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
EP3828275A1 (en) | 2013-05-01 | 2021-06-02 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ttr expression |
US9714421B2 (en) | 2013-05-01 | 2017-07-25 | Ionis Pharmaceuticals, Inc. | Compositions and methods |
US10883104B2 (en) | 2013-05-01 | 2021-01-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating apolipoprotein (a) expression |
WO2014179620A1 (en) | 2013-05-01 | 2014-11-06 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
EP3690049A1 (en) | 2013-05-01 | 2020-08-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating apolipoprotein c-iii expression |
US9932580B2 (en) | 2013-05-01 | 2018-04-03 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating HBV expression |
US9932581B2 (en) | 2013-05-01 | 2018-04-03 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating apolipoprotein C-III expression |
WO2014179627A2 (en) | 2013-05-01 | 2014-11-06 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating hbv and ttr expression |
US9879265B2 (en) | 2013-06-27 | 2018-01-30 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
US11739332B2 (en) | 2013-06-27 | 2023-08-29 | Roche Innovation Center Copenhagen A/S | Antisense oligomers targeting PCSK9 |
US10443058B2 (en) | 2013-06-27 | 2019-10-15 | Roche Innovation Center Copenhagen A/S | Antisense oligomers targeting PCSK9 |
US10370668B2 (en) | 2013-06-27 | 2019-08-06 | Roche Innovation Center Copenhagen A/S | Manufacture of antisense oligomers and conjugates targeting PCSK9 |
US10385342B2 (en) | 2013-06-27 | 2019-08-20 | Roche Innovation Center Copenhagen A/S | Methods of treatment using antisense oligomers and conjugates targeting PCSK9 |
US9943604B2 (en) | 2013-09-20 | 2018-04-17 | Ionis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
US10358643B2 (en) | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
US9926556B2 (en) | 2014-04-28 | 2018-03-27 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
EP3647318A1 (en) | 2014-04-28 | 2020-05-06 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
WO2015168172A1 (en) | 2014-04-28 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
US9382540B2 (en) | 2014-05-01 | 2016-07-05 | Isis Pharmaceuticals, Inc | Compositions and methods for modulating angiopoietin-like 3 expression |
WO2015168589A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
EP3974534A1 (en) | 2014-05-01 | 2022-03-30 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
US11312964B2 (en) | 2014-05-01 | 2022-04-26 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
EP3608406A1 (en) | 2014-05-01 | 2020-02-12 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor b expression |
WO2015168618A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
EP3862362A2 (en) | 2014-05-01 | 2021-08-11 | Ionis Pharmaceuticals, Inc. | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression |
EP3845547A1 (en) | 2014-05-01 | 2021-07-07 | Ionis Pharmaceuticals, Inc. | Galnac3 conjugated modified oligonucleotide for modulating angiopoietin-like 3 expression |
US11732265B2 (en) | 2014-05-01 | 2023-08-22 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor B expression |
US10280423B2 (en) | 2014-05-01 | 2019-05-07 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor B expression |
EP4219718A2 (en) | 2014-05-01 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor b expression |
US9994855B2 (en) | 2014-05-01 | 2018-06-12 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
US10793862B2 (en) | 2014-05-01 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
US10875884B2 (en) | 2014-05-01 | 2020-12-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
EP3757215A2 (en) | 2014-05-01 | 2020-12-30 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
US12013403B2 (en) | 2014-09-12 | 2024-06-18 | Biogen Ma Inc. | Compositions and methods for detection of SMN protein in a subject and treatment of a subject |
EP4092119A2 (en) | 2015-07-10 | 2022-11-23 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
WO2017053722A1 (en) | 2015-09-24 | 2017-03-30 | Ionis Pharmaceuticals, Inc. | Modulators of kras expression |
WO2017079745A1 (en) | 2015-11-06 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
EP4119569A1 (en) | 2015-11-06 | 2023-01-18 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
US11319536B2 (en) | 2015-11-06 | 2022-05-03 | Ionis Pharmacueticals, Inc. | Modulating apolipoprotein (a) expression |
US10557137B2 (en) | 2015-11-06 | 2020-02-11 | Ionis Pharmaceuticals, Inc. | Modulating apolipoprotein (a) expression |
US10246709B2 (en) | 2016-03-07 | 2019-04-02 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
WO2018014041A2 (en) | 2016-07-15 | 2018-01-18 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of smn2 |
EP4206213A1 (en) | 2016-07-15 | 2023-07-05 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of smn2 |
US10294474B2 (en) | 2016-09-02 | 2019-05-21 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
US11174481B2 (en) | 2016-09-02 | 2021-11-16 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
US11400161B2 (en) | 2016-10-06 | 2022-08-02 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
EP4309732A2 (en) | 2017-03-24 | 2024-01-24 | Ionis Pharmaceuticals, Inc. | Modulators of pcsk9 expression |
WO2019140452A1 (en) | 2018-01-15 | 2019-07-18 | Ionis Pharmaceuticals, Inc. | Modulators of dnm2 expression |
US11149264B2 (en) | 2018-02-12 | 2021-10-19 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
US11332733B2 (en) | 2018-02-12 | 2022-05-17 | lonis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
WO2019217527A1 (en) | 2018-05-09 | 2019-11-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing fxi expression |
WO2020033748A1 (en) | 2018-08-08 | 2020-02-13 | Arcturus Therapeutics, Inc. | Compositions and agents against nonalcoholic steatohepatitis |
WO2020061200A1 (en) | 2018-09-19 | 2020-03-26 | Ionis Pharmaceuticals, Inc. | Modulators of pnpla3 expression |
WO2021074772A1 (en) | 2019-10-14 | 2021-04-22 | Astrazeneca Ab | Modulators of pnpla3 expression |
US11299737B1 (en) | 2020-02-28 | 2022-04-12 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating SMN2 |
US11447521B2 (en) | 2020-11-18 | 2022-09-20 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
WO2023056440A1 (en) | 2021-10-01 | 2023-04-06 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0862439A1 (en) | 1998-09-09 |
CA2238379A1 (en) | 1997-06-12 |
CN1120707C (en) | 2003-09-10 |
US5994517A (en) | 1999-11-30 |
EP0862439A4 (en) | 2001-01-10 |
AU1039397A (en) | 1997-06-27 |
CN1211923A (en) | 1999-03-24 |
JP2000501414A (en) | 2000-02-08 |
TW520293B (en) | 2003-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5994517A (en) | Ligands to enhance cellular uptake of biomolecules | |
US20030119724A1 (en) | Ligands to enhance cellular uptake of biomolecules | |
Hangeland et al. | Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleoside methylphosphonates covalently linked with a neoglycopeptide, YEE (ah-GalNAc) 3 | |
US7262177B2 (en) | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use | |
Manoharan et al. | Oligonucleotide conjugates: alteration of the pharmacokinetic properties of antisense agents | |
US6525031B2 (en) | Targeted Oligonucleotide conjugates | |
US6656730B1 (en) | Oligonucleotides conjugated to protein-binding drugs | |
US5851548A (en) | Liposomes containing cationic lipids and vitamin D | |
US20040054132A1 (en) | Methods and compositions for lipidization of hydrophilic molecules | |
US20080071069A1 (en) | Conjugates and processes for their preparation and their use for transporting molecules across biological membranes | |
Hangeland et al. | Tissue Distribution and Metabolism of the [32P]-Labeled Oligodeoxynucleoside Methylphosphonate-Neoglycopeptide Conjugate,[YEE (ah-GalNAc) 3]-SMCC-AET-pUmp T 7, in the Mouse | |
WO2023081893A1 (en) | Intracellular targeting of oligonucleotides | |
CA1319119C (en) | Nucleic acid chelate conjugate as therapeutic and diagnostic agents | |
Watanabe et al. | Labeling of phosphorothioate antisense oligonucleotides with yttrium-90 | |
Manoharan et al. | Conjugated antisense oligonucleotides | |
JP2004502649A (en) | Negatively charged peptide nucleic acid derivative, drug and method for producing the same | |
EP1129725A2 (en) | Oligonucleotide conjugates | |
Liu et al. | Cytosine residues influence kidney accumulations of 99mTc-labeled morpholino oligomers | |
JPH0799976A (en) | Modified oligonucleotide | |
AU2036099A (en) | Conjugates made of metal complexes and oligonucleotides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96199495.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996941146 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2238379 Country of ref document: CA Ref document number: 2238379 Country of ref document: CA Kind code of ref document: A Ref document number: 1997 521121 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1996941146 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |